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Abstract   
 
SPROUTY-2 (SPRY2) regulates receptor tyrosine kinase signalling and therefore cell 
growth and differentiation. Here we show that SPRY2 expression in colon cancer cells is 
inhibited by the active vitamin D metabolite 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3) 
through E-cadherin-dependent and -independent mechanisms. In turn, SPRY2 
represses both basal and 1,25(OH)2D3-induced E-cadherin expression. In line with this, 
SPRY2 induces ZEB1 RNA and protein, but not that of other epithelial-to-mesenchymal 
transition inducers that repress the CDH1/E-cadherin promoter. Consistently, SPRY2 
and E-cadherin protein levels inversely correlate in colon cancer cell lines and 
xenografted tumours. Moreover, SPRY2 knock-down by shRNA increases CDH1/E-
cadherin expression and, reciprocally, CDH1/E-cadherin knock-down increases that of 
SPRY2. In colon cancer patients, SPRY2 is up-regulated in undifferentiated high grade 
tumours and at the invasive front of low grade carcinomas. Quantification of protein 
expression in 34 tumours confirmed an inverse correlation between SPRY2 and E-
cadherin. Our data demonstrate a tumourigenic action of SPRY2 that is based on the 
repression of E-cadherin probably via the induction of ZEB1, and a reciprocal 
regulation of SPRY2 and E-cadherin that dictates cell phenotype. We propose SPRY2 as 
a candidate novel marker for high-grade tumours and a target of therapeutic 
intervention in colon cancer. 
 




Many epidemiological and animal studies indicate that the active vitamin D metabolite 1α,25-
dihydroxyvitamin D3 (1,25(OH)2D3) affords protection against colon cancer (Campbell and 
Adorini, 2006; Deeb et al., 2007; Eelen et al., 2007). A causal link between vitamin D 
deficiency and colon cancer has recently been considered probable by the International 
Agency for Research on Cancer (IARC, 2008).  
We have reported that 1,25(OH)2D3 inhibits the proliferation and promotes the 
differentiation of human colon cancer cells via the induction of the adhesion molecule E-
cadherin and the antagonism of the Wnt/β-catenin pathway (Pálmer et al., 2001; Aguilera et 
al., 2007)). A transcriptomic analysis revealed a decrease in the level of SPROUTY-2 (SPRY2) 
RNA upon treatment of SW480-ADH cells with 1,25(OH)2D3 (5.6-fold at 4 hours) (Pálmer et 
al., 2003). SPRY2 protein is a member of a highly conserved family (SPRY1-4) of 
intracellular modulators of several growth factor receptors tyrosine kinase (RTK) (Cabrita and 
Christofori, 2008). Its effect on RTK-Ras-ERK signalling depends strongly on receptor and 
cell-context (Cabrita and Christofori, 2008). SPRY2 inhibits fibroblast growth factor (FGF) 
ERK signalling activation whereas it potentiates ERK activation by epidermal growth factor 
(EGF) in some cell types (Egan et al., 2002; Rubin et al., 2003). Two mechanisms for this 
potentiation have been proposed: a) competition with EGF receptor (EGFR) for binding to the 
c-Cbl E3 ubiquitin ligase via association with the endocytic adapter CIN85 which would 
prevent EGFR endocytosis and degradation (Wong et al., 2002; Haglund et al., 2005); and b) 
interference with activated EGFR trafficking to late endosomes by interaction with the 
hepatocyte growth factor (HGF)-regulated tyrosine kinase substrate (Hrs) (Kim et al., 2007). 
How SPRY2 exerts such distinct effects on FGF and EGF signalling is unclear. 
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Likewise, SPRY2 regulation is complex. SPRY2 transcription is induced by EGF, 
FGFs, HGF and platelet-derived growth factor (PDGF), which also promotes degradation of 
SPRY2 protein in a negative feed-back process (Cabrita and Christofori, 2008). Conversely, 
transforming growth factor (TGF)-β1 inhibits mouse Spry2 transcription and reduces protein 
stability in fibroblasts by promoting its lysosomal degradation (Ding et al., 2007). SPRY2 
expression in human cancers depends on tumour type. SPRY2 is down-regulated in breast, 
prostate, and liver tumours and in B-cell diffuse lymphoma, which would suggest a tumour 
suppressive role (McKie et al., 2005; Fong et al., 2006; Lo et al., 2006; Sánchez et al., 2008; 
Frank et al., 2009). In contrast, SPRY2 is up-regulated in melanoma cell lines concomitantly 
to mutation of N-RAS and B-RAF (Tsavachidou et al., 2004; Bloethner et al., 2005). Data on 
colon cancer are scarce and inconclusive: only one study has reported opposite changes of 
SPRY2 RNA levels in a low number of patients, and the tumour characteristics were not 
described (Lo et al., 2006). 
In this study we show that SPRY2 decreases both the basal and 1,25(OH)2D3-induced 
expression of E-cadherin, leading to the inhibition of the adhesive epithelial phenotype of 
colon cancer cells. Consistently, SPRY2 induces the epithelial-to-mesenchymal transition 
(EMT) gene ZEB1. Additionally, we show that SPRY2 gene is inhibited by 1,25(OH)2D3 in 
colon cancer cells in part due to the induction of E-cadherin-mediated cell adhesion. The 
reciprocal repression between SPRY2 and E-cadherin is substantiated by the inverse 
correlation of their level of expression in a panel of colon cancer cell lines and in xenografted 
tumours. In colon cancer patients, SPRY2 expression also correlates inversely with that of E-
cadherin. Together, these data indicate that SPRY2 is a negative regulator of E-cadherin and 






1,25(OH)2D3 decreases SPRY2 expression in human colon cancer cells. 
 Treatment of SW480-ADH cells with 10-7 M 1,25(OH)2D3 decreased SPRY2 RNA 
expression by 50%, validating a previous transcriptomic study (Pálmer et al., 2003) (Figure 
1a). This decrease was even stronger at the protein level (preferentially of the upper, 
phosphorylated band) (Figure 1b, left). The inhibition was specific, as the level of SPRY4 did 
not change (Figure 1b, right), and it was not observed for other nuclear receptor ligands such 
as dexamethasone, estradiol, or progesterone (Figure 1c). A kinetics analysis showed a 
progressive reduction of SPRY2 protein (Figure 1d). Supporting a general effect, 
1,25(OH)2D3 decreased SPRY2 expression in a panel of human colon cancer cell lines (HT29, 
KM12SM, DLD-1, SW1417) (Figure 1e).  The RNA polymerase II inhibitor actinomycin D 
(ActD) and the translation inhibitor cycloheximide (Chx) were used to further investigate the 
mechanism of SPRY2 repression. Pretreatment with ActD showed that SPRY2 RNA half-life 
is only ~40 min, which makes putative shortening by 1,25(OH)2D3 difficult to assess 
(Supplementary Fig. 1a). In order to overcome this limitation, we added ActD (30 min) to 
cells after (19 h) 1,25(OH)2D3 treatment and found that the RNA decay was similar in 
1,25(OH)2D3-treated and control cells (24 and 29% reduction in SPRY2 RNA level, 
respectively). However, this result could not be confirmed at longer timepoints due to the 
short SPRY2 RNA half-life (Supplementary Fig. 1b). Addition of Chx prior to 1,25(OH)2D3 
abrogated the decrease of SPRY2 RNA expression by 1,25(OH)2D3 (Supplementary Fig. 1c). 
By contrast, Chx did not prevent the decrease of SPRY2 RNA when added 19 h after 
1,25(OH)2D3 possibly because proteins responsible for this effect were already synthesized 
(Supplementary Fig. 1d). Pretreatment with Chx hampered the decrease of SPRY2 protein by 
1,25(OH)2D3 (Supplementary Fig. 2a) while its addition after 1,25(OH)2D3 did not prevent it 
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(Supplementary Fig. 2b). In these experiments the upper band of SPRY2 showed higher 
stability than the lower band. Together, these data support that 1,25(OH)2D3 inhibits SPRY2 
expression indirectly through intermediate proteins that regulate SPRY2 transcription and 
protein stability. 1,25(OH)2D3 does not alter the stability of E-cadherin RNA (Pálmer et al., 
2001) or protein (Supplementary Figure 3). 
 
SPRY2 inhibits basal and 1,25(OH)2D3-induced E-cadherin expression and epithelial 
phenotype. 
 To examine the importance of SPRY2 repression by 1,25(OH)2D3, we generated 
SW480-ADH cells stably expressing an exogenous human SPRY2 cDNA (SPRY2 cells) or an 
empty vector (Mock cells). Ectopic SPRY2 expression did not affect cell morphology in the 
absence of treatment, but strongly inhibited the intercellular adhesion induced by 
1,25(OH)2D3 (Figure 2a). 1,25(OH)2D3 also decreased the amount of exogenous AU5-tagged 
SPRY2 (again preferentially of the upper band) further supporting a posttranscriptional 
regulation at the level of protein stability (Figure 2b). 
We then investigated whether the effect of SPRY2 on cell phenotype could be a 
consequence of a general blockade of 1,25(OH)2D3 action. To this end, we first analyzed the 
expression of vitamin D receptor (VDR), a member of the nuclear receptor superfamily that 
mediates all known actions of 1,25(OH)2D3 (Ordónez-Morán et al., 2008). As reported in 
many systems, 1,25(OH)2D3 increased VDR protein (Wiese et al., 1992; Pike et al., 2007). 
SPRY2 did not change basal VDR expression or its increase by ligand (Figure 2c). Moreover, 
a consensus vitamin D response element (VDRE) was similarly activated by 1,25(OH)2D3 in 
Mock and SPRY2 cells (Figure 2d). Additionally, we observed that SPRY2 did not alter the 
repression of c-MYC protein by 1,25(OH)2D3 (Figure 2e). Together, these results indicate that 
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SPRY2 specifically represses the induction of an adhesive phenotype by 1,25(OH)2D3 without 
affecting its ability to activate or repress gene expression. 
 E-cadherin is the main molecule responsible for intercellular adhesion in epithelia and 
it is induced by 1,25(OH)2D3 in human colon cancer cells (Pálmer et al., 2001; Ordónez-
Morán et al., 2008). We examined whether it could be regulated by SPRY2. Using qRT-PCR 
we found the level of CDH1/E-cadherin RNA to be much lower (∼70% reduction) in SPRY2 
cells than in Mock cells (Figure 3a). Likewise, the basal expression of E-cadherin protein was 
also lower in SPRY2 cells than in Mock cells, and >50% reduction was found in the presence 
of 1,25(OH)2D3 (Figure 3b). Again, 1,25(OH)2D3 decreased the amount of exogenous SPRY2 
protein. These results were confirmed by immunofluorescence analyses, which showed a 
reduction of plasma membrane E-cadherin and of intercellular adhesion in SPRY2 cells as 
compared to Mock cells following 1,25(OH)2D3 treatment (Figure 3c). 
To search for an explanation for the inhibition of E-cadherin expression in SPRY2 
cells, we analyzed the expression of EMT inducers that are transcriptional repressors of 
CDH1/E-cadherin (Peinado et al., 2007). In line with its inhibitory effect on E-cadherin, 
SPRY2 increased the expression of ZEB1 RNA (Figure 3d). In contrast, no changes were 
found for SNAI1, SNAI2/SLUG or ZEB2. The increase of ZEB1 protein by SPRY2 was 
confirmed by Western blot analysis (Figure 3e). In accordance with the up-regulation of ZEB1 
by SPRY2, the activity of CDH1/E-cadherin promoter was much lower in SPRY2 cells than 
in Mock cells (Figure 3f). ZEB1 knock-down by shRNA increased E-cadherin protein 
expression in Mock cells but did not alter SPRY2 level (Supplementary Figure 4a and b). 
However, no reduction in ZEB1 expression by shRNA was achieved in cells overexpressing 
AUG-tagged SPRY2 (Supplementary Figure 4c). In summary, these data indicate that the 
blockade of cell adhesiveness by SPRY2 is at least partially due to ZEB1-mediated E-
cadherin down-regulation.  
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E-cadherin and SPRY2 mutually repress in colon cancer cells. 
 We studied the expression of E-cadherin and SPRY2 proteins in a panel of human 
colon cancer cell lines. A strong inverse relation was found, as the cell lines with high E-
cadherin contained low SPRY2 levels (KM12SM, HT29, and SW1417) whereas those with 
low E-cadherin contained high SPRY2 levels (SW480-R, LS174T, and rat CT26) (Figure 4a). 
Remarkably, no inverse relation was found in SW48 cells that express E-cadherin but 
nevertheless show little adhesiveness due to the mutation of p120-catenin, a known regulator 
of E-cadherin protein stability and localization (Ireton et al., 2002). In contrast to what 
happened with SPRY2, the level of SPRY4 expression was unrelated to that of E-cadherin in 
the panel of cell lines studied (Supplementary Figure 5a). 
The possibility that the repression of SPRY2 by 1,25(OH)2D3 could be linked to the 
induction of E-cadherin was first studied in dose-curve and kinetics experiments using 
SW480-ADH cells. Similarity was found between both 1,25(OH)2D3 effects (Figures 4 b and 
c). To further investigate this, we studied SPRY2 expression in SW480-ADH cells stably 
expressing an exogenous E-cadherin gene (SW480-ADH-E-cadh). These cells contain high 
levels of E-cadherin and show strong adhesiveness (Aguilera et al., 2007). In the absence of 
1,25(OH)2D3, the level of SPRY2 RNA and protein was lower in SW480-ADH-E-cadh cells 
than in Mock cells (Figures 4 d and e). This suggested that E-cadherin, or the intercellular 
adhesion that it causes, may mediate the inhibition of SPRY2. In line with this idea, highly 
tumourigenic SW480-R cells (that contained very low E-cadherin and VDR levels and, like 
SW480-ADH cells, were derived from the parental SW480 cell line (Tomita et al., 1992; 
Pálmer et al., 2001)), showed strong SPRY2 expression  (Supplementary Figure 5b). These 
data however did not discriminate whether E-cadherin or intercellular adhesion itself was 
responsible for SPRY2 inhibition. To solve this, we used LS174T cells that lack E-cadherin 
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expression due to a mutation (Efstathiou et al., 1999). In LS174T cell cultures, the expression 
of SPRY2 RNA and protein was lower (40%) at high confluence than at lower confluence 
(Figure 4f and g). This result emphasizes the importance of cell adhesion for SPRY2 
repression. Interestingly, 1,25(OH)2D3 further reduced SPRY2 RNA and protein expression in 
SW480-ADH-E-cadh (Figures 4 d and e), and SPRY2 protein expression in DLD-1 and 
KM12SM cells (Suppl. Figure 5c) without affecting the high level of E-cadherin RNA or 
protein in these cell lines. This indicates that at least part of the repressive effect of 
1,25(OH)2D3 on SPRY2 is independent of E-cadherin induction.  
We next examined the effect of CDH1/E-cadherin on SPRY2 expression, and vice 
versa. To improve our analysis of the effect of E-cadherin knock-down in SW480-ADH cells 
that express low basal levels, we used highly confluent cultures. CDH1/E-cadherin knock-
down by shRNA in three colon cancer cell lines (SW480-ADH, HT29, DLD-1) decreased 
intercellular adhesion (Figure 5a) and increased the level of SPRY2, preferentially of the 
upper band (Figure 5b) but not that of SPRY1, 3 or 4 (Supplementary Figure 6a). ZEB1 
protein expression increased only weakly in CDH1/E-cadherin knock-down SW480-ADH 
cells and was not detected in HT29 or DLD-1 cells (Figure 5c).  
Reciprocally, SPRY2 knock-down increased E-cadherin expression in SW480-ADH 
cells (Figure 6a) without affecting that of SPRY1, 3 or 4 (Supplementary Figure 6b). 
1,25(OH)2D3 further reduced SPRY2 expression in SPRY2 shRNA cells, leading to higher E-
cadherin level (Figure 6a). SPRY2 shRNA cells showed slightly increased intercellular 
adhesion in both the absence and the presence of 1,25(OH)2D3 (Figure 6b). SPRY2 knock-
down decreased weakly ZEB1 expression suggesting that other factors may be responsible for 
basal ZEB1 expression (Figure 6c).  
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Collectively, these results show a reciprocal regulation of SPRY2 and E-cadherin in 
colon cancer cells. Both are controlled by 1,25(OH)2D3, which represses SPRY2 and induces 
E-cadherin expression. 
 
Expression of SPRY2 and E-cadherin inversely correlate in human colon tumours. 
 To investigate SPRY2 expression in human colon tumours we first studied 
immunodeficient mice xenografted with SW480-ADH cells expressing hemagglutinin (HA)-
tagged murine Snail1 (SNAIL-HA cells) (Pálmer et al., 2004). As expected from the 
repressive effect of SNAIL1 on the CDH1/E-cadherin promoter (Batlle et al., 2000; Cano et 
al., 2000), in these tumours, the expression of Snail1-HA and of E-cadherin were mutually 
exclusive (Figures 7 a-c). We found coincident expression of SPRY2 and Snail1-HA (Figure 
7 d-f), and, in contrast, down-regulation of SPRY2 in tumour areas showing high levels of E-
cadherin protein (Figures 7 g-i). These data indicate an inverse correlation between the 
expression of E-cadherin and SPRY2 in xenografted tumours.  
Next, we analyzed biopsies from human colon cancer patients. First, we studied the 
expression of E-cadherin and SPRY2 in a panel of adenocarcinomas of distinct differentiation 
grades (Figures 8 a-f). Low grade tumours with strong cytokeratin staining showed high 
levels of E-cadherin and low levels of SPRY2 (Figures 8 g and j). In contrast, high grade 
tumours that had weak cytokeratin staining showed low levels of E-cadherin and high levels 
of SPRY2 in carcinoma cells (Figures 8 i and l). Moderately differentiated tumours (G2) 
displayed intermediate levels of E-cadherin and decreased SPRY2 expression (Figures 8 h 
and k). The inverse correlation between E-cadherin and SPRY2 was particularly strong in 
poorly differentiated neuroendocrine colon carcinomas (Supplementary Figure 7). 
Remarkably, in low grade (G1) tumours SPRY2 was up-regulated at the invasion front, in 
cells that had escaped from the tumour mass (Figures 8 m and n). SPRY2 and E-cadherin 
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protein expression was then quantified by immunofluorescence analysis in duplicate tumour 
samples spotted on a tissue microarray (Supplementary Information). Tumours from 34 
patients were informative. A scattergram showing the quantification of fluorescence revealed 
a significant inverse correlation between SPRY2 and E-cadherin expression (Spearman r = -
0.42, P = 0.013) (Figure 9a). While a subset of tumours contained low levels of SPRY2 and 
E-cadherin, putatively due to other factors, no tumours were found with concomitant high 
expression of these two proteins (Figure 9a). Splitting the tumours into two groups by the 
median value of E-cadherin fluorescence further confirmed the inverse correlation (Kruskal-
Wallis test, P = 0.003) (Figure 9b). Moreover, the comparative analysis of SPRY2 expression 
and several clinico-pathological parameters (Supplementary Table 1) revealed a strong trend 





Our study reveals a tumourigenic activity of SPRY2 in human colon cancer based on its 
capacity to inhibit E-cadherin expression. In addition, we demonstrate that 1,25(OH)2D3 
down-regulates SPRY2 and that SPRY2 and E-cadherin play opposite roles in controlling cell 
differentiation (Figure 10). These effects strongly indicate that SPRY2 promotes the 
tumourigenic phenotype of colon carcinoma cells. Further supporting this, SPRY2 is up-
regulated in high grade tumours and at the invasion front of low grade tumours. 
The repression of E-cadherin is critical for tumourigenesis. E-cadherin dysfunction 
promotes tumour progression and metastasis by several mechanisms that include loss of 
intercellular adhesion, induction of EMT, anoikis resistance, and gain of invasion and 
proliferative capacity. This is explained by the potential of E-cadherin to inhibit mitogenic 
signalling from EGFR and other growth factor receptors and the Wnt/β-catenin pathway, and 
to maintain the differentiated epithelial phenotype through the regulation of intercellular 
adhesion and multiple transcription factors (Frixen et al., 1991; Vleminckx et al., 1991; 
Miyaki et al., 1995; Perl et al., 1998; Christofori and Semb, 1999; Qian et al., 2004; Perrais et 
al., 2007; Jeanes et al., 2008; Onder et al., 2008). E-cadherin down-regulation by SPRY2 is 
found at both RNA and protein levels, and correlates with the up-regulation of ZEB1 RNA 
and protein. This EMT inducer is a transcriptional repressor of CDH1/E-cadherin and other 
epithelial genes and may thus mediate the inhibitory effect of SPRY2. The increase of E-
cadherin expression upon ZEB1 knock-down supports this notion. Unfortunately, transfected 
ZEB1 shRNA did not decrease ZEB1 expression in SPRY2 cells in repeated attempts, perhaps 
due to its induction by exogenous SPRY2. The tumourigenic activity of SPRY2 is 
emphasized by the recent findings that ZEB1 inhibits cell polarity and differentiation and is 
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associated with tumour cell migration, invasion, and metastasis, in particular in colon 
carcinoma (Schmalhofer et al., 2009). 
Our data show that 1,25(OH)2D3 increases E-cadherin expression at least in part 
through SPRY2 down-regulation. Because 1,25(OH)2D3 inhibits SPRY2 in colon cancer cells 
even in the absence of E-cadherin, as occurs in E-cadherin-deficient LS174T cells, we 
conclude that SPRY2 is repressed by this pleiotropic hormone through both E-cadherin-
dependent and -independent mechanisms. The data obtained using ActD and Chx and the 
decrease of exogenous SPRY2 by 1,25(OH)2D3 favour an indirect regulation mediated by 
intermediary proteins that affect SPRY2 transcription and SPRY2 protein stability. The 
intimate basis of E-cadherin-dependent regulation is unknown, but may be responsible for, or 
contribute to these mechanisms.  
 The reciprocal repression between SPRY2 and E-cadherin is substantiated by the 
inverse relation of their expression levels in a panel of colon cancer cell lines. Additionally, 
the use of shRNA showed their mutual down-regulation. Dose-curves and kinetics of E-
cadherin induction and SPRY2 repression by 1,25(OH)2D3 are similar, suggesting that the two 
effects are initially independent, although they may later be linked and enhanced by the 
mutual regulation of E-cadherin and SPRY2. Thus, the finding that SPRY2 expression 
decreases with cell confluence suggests that this effect relies on adhesion-dependent 
signalling. In line with this hypothesis, it has recently been shown that high cell density 
activates p38MAPK, which phosphorylates and activates Siah2 ubiquitin ligase and so 
decreases SPRY2 levels (Swat et al., 2009). Notably, 1,25(OH)2D3 has recently been reported 
to transiently activate p38MAPK in many cell lines of human and rodent origin. Moreover, 
p38MAPK, via downstream activation of MSK1, is essential for gene regulation and Wnt 
antagonism by 1,25(OH)2D3 (Ordónez-Morán et al., 2008).  
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 Mutual down-regulation between E-cadherin and ligand activated EGFR has been 
described (Qian et al., 2004). Mutation of E-cadherin in diffuse-type gastric carcinoma 
associates with increased activation of EGFR (Bremm et al., 2008). In non-small cell lung 
cancer E-cadherin plays an important role in prognosis and progression and interacts with 
EGFR. In this neoplasia E-cadherin and ZEB1 expression correlate with sensitivity to the 
EGFR inhibitor genitinib (Witta et al., 2006). Likewise, colorectal and pancreatic cell lines 
with mutated or no E-cadherin are also insensitive to the EGFR inhibitor erlotinib (Buck et 
al., 2007). Our results suggest that SPRY2, which potentiates ERK activation by EGF (Egan 
et al., 2002; Rubin et al., 2003) is a good candidate to mediate the crosstalk between ligand-
activated EGFR and both E-cadherin and 1,25(OH)2D3/VDR. Additionally, our study supports 
a master role of 1,25(OH)2D3 in promoting differentiation and preventing excessive 
proliferation of colon cancer cells through the repression of SPRY2 and the induction of 
CDH1/E-cadherin.  
The effects of SPRY2 revealed here, its pattern of expression that is opposite to that of 
E-cadherin, and its up-regulation in high grade tumours strongly argue in favour of a 
tumourigenic activity in human colon cancer. This contrasts with the proposed tumour 
suppressor activity of SPRY2 in breast, prostate, and lung cancer on the basis of its decreased 
expression as compared to normal tissue (McKie et al., 2005; Fong et al., 2006; Lo et al., 
2006; Sánchez et al., 2008; Frank et al., 2009). Concordantly with our results, a meta-analysis 
of data available at the Oncomine database supports that SPRY2 expression is higher in colon 
tumours than in other neoplasias (Rhodes et al., 2004) (Supplementary Figure 8). In summary, 
SPRY2 has an unanticipated tumourigenic activity and is a potential marker of malignancy 
and pharmacological target in colon cancer. 
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Materials and Methods 
 
Cells and cell culture. 
Human colon cancer cell lines SW480-ADH and SW480-R cells (Pálmer et al., 2001), HT29, 
DLD-1, KM12SM (provided by Dr. A. Fabra, Barcelona), SW1417 and LS174T, human 
293T cells and rat intestine cell line CT26 were cultured in DMEM plus 10% foetal bovine 
serum (Invitrogen). SW480-ADH-E-cadh cells were previously described (Aguilera et al., 
2007). All experiments using 1,25(OH)2D3 (provided by Dr. R. Bouillon and A. Verstuyf, 
Leuven, Belgium, and Dr. J. P. van de Velde, Weesp, The Netherlands) were performed in 
medium supplemented with charcoal-treated serum.  
 
Antibodies and reagents. 
We used primary mouse monoclonal antibodies against E-cadherin and β-catenin (BD 
Transduction Laboratories), c-MYC (Santa Cruz Biotechnology, sc-40), AU5 (Covance), 
SPRY2 (Abnova), Pan-cytokeratin (Novocastra); rat monoclonal antibodies against VDR 
(Chemicon) and HA (BABCO); rabbit polyclonal antibodies against SPRY2 (Upstate), 
SPRY1, SPRY3 and SPRY4 (Abcam); and goat polyclonal antibodies against ZEB1, β-actin 
and Lamin B (Santa Cruz Biotecnology, sc-10572, sc-1616 and sc-6216, respectively). 
Secondary antibodies used: Alexa 488-conjugated goat anti-mouse and goat anti-rabbit IgG 
(H + L) (Molecular Probes) and Alexa 546-conjugated goat anti-mouse, goat anti-rabbit, and 
goat anti-rat IgG (H + L) (Molecular Probes). Nuclei were stained using DAPI (Molecular 




Cells were transfected using the jetPEI reagent (PolyPlus Transfection). Firefly (Luc) and 
Renilla reniformis luciferase (Rluc) activities were measured separately using the Dual 
Luciferase reagent kit (Promega). Luc activity was normalized to the Rluc activity. All 
experiments were performed in quadruplicate. The promoter construct for CDH1/E-cadherin 
was as previously reported (Pálmer et al., 2001). The 4XVDRE-DR3-Tk-Luc construct was 
provided by Dr. C. Carlberg (University of Luxembourg). Mock and SPRY2 cells were 
generated by stable transfection of SW480-ADH cells with pCEFL-KZ-AU5 or pCEFL-KZ-
AU5-hSPRY2 plasmids (Martínez et al., 2007). 293T cells were transfected with pcDNA3-
ZEB1 expression plasmid provided by Dr. A. García de Herreros (Instituto Municipal de 
Investigación Médica, Barcelona). 
 
Gene silencing. 
To knock-down SPRY2 cells were infected with lentiviral particles containing a U6 promoter 
driving an shRNA targeting the respective RNA. Mission® shRNA lentiviral particles against 
human SPRY2 or scramble negative control (Sigma) were used. For E-cadherin knock-down 
we used constructs belonging to the MISSION TRC shRNA library (Sigma, provided by Dr. 
E. Batlle, University of Barcelona). ZEB1 knock-down was performed by transfection with 
pSUPER shZEB1 kindly provided by Dr. A. García de Herreros. 
 
Quantitative RT-PCR.  
Total cellular RNA was purified using RNeasy mini kit (Qiagen). Primers used are listed in 
Table S2. Values were normalized versus housekeeping gene succinate dehydrogenase 
complex subunit A (SDHA) or 18S ribosomal RNA (18S). In some experiments the reaction 
was performed in a Light-Cycler apparatus using the LightCycler-FastStart DNA 
MasterPLUS SYBR Green I Kit (Roche Diagnostics). Specific annealing temperature showed 
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in Table S2 for 5 s, and elongation at 72ºC for 5 s. In other cases we used the 7500 StepOne 
Plus™ Real-Time PCR System and the TaqMan SPRY2 Hs00183386_m1 probe (Applied 
Biosystems). All experiments were performed in triplicate. 
 
Western blot. 
Proteins were separated by SDS-PAGE. After blotting onto a PVDF membrane, proteins were 
revealed following the ECL technique (Amersham). Different exposure times of the films 
were used to ensure that bands were not saturated. Quantification of the films was done by 
densitometry using ImageJ software.  
 
Immunofluorescence and confocal microscopy of cells and tissues. 
Cells were fixed in methanol at -20ºC for 3 min and then washed four times in PBS. Cells 
were incubated with the primary antibodies diluted in PBS for 1 h at 37ºC. After four washes 
in PBS, the cells were incubated with secondary antibodies for 45 min at room temperature, 
washed three times in PBS and mounted using Prolong Gold antifade reagent (Molecular 
Probes-Invitrogen). Conventional fixed and paraffin-embedded sections of human tumours or 
tumours generated by SNAIL-HA cells in immunodeficient scid mice (Pálmer et al., 2004) 
were prepared and immunolabelled as described elsewhere (Silva-Vargas et al., 2005). 
Briefly, antigens were retrieved by microwaving in 10 mM citrate buffer (pH 6.0) for 10 min 
and permeabilized with 0.2% Triton X-100 (Sigma). Non-specific binding was blocked by 
incubating the sections in 10% BSA (Sigma) for 1 h. Cell imaging was performed on a Leica 
TCS SP5 DMI6000 microscope using argon ion (488 nm), HeNe (543 nm) and violet diode 
(405 nm) lasers. Images were acquired sequentially by direct register using Leica Confocal 
Software (LAS AF). Immunofluorescence signals were quantified as described in 
Supplementary Information. 
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SNAIL-HA cells were injected in severe immunodeficient female scid mice obtained 
from The Jackson Laboratories (Bar Harbor, USA) (Pálmer et al., 2004). The maintenance 
and handling of animals were as recommended by the European Union (ECC Directive of 
November 24th, 1986, 86/609/EEC) and all experiments were approved by the Animal 
Experimentation Committee at our Instituto de Investigaciones Biomédicas, Madrid. Every 
effort was made to minimize animal suffering and to reduce the number of animals used.  
Patients were considered sporadic cases because no clinical antecedents of Familial 
Adenomatous Polyposis were reported and those with clinical criteria of hereditary non-
polyposis colorectal cancer (Amsterdam criteria) were excluded. All patients of the study 
gave written informed consent. The protocol was approved by the Research Ethics Board of 
Hospital Vall d’Hebron, Barcelona. 
 
Other Methods. The remaining materials and methods section is provided as Supplementary 
Information. 
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Figure 1. 1,25(OH)2D3 represses SPRY2 expression in colon cancer cells. (a) qRT-PCR 
analysis of SPRY2 RNA levels in SW480-ADH cells treated with 10-7 M 1,25(OH)2D3 for the 
indicated times. SDHA RNA expression was used for normalization. (b) Western blot analysis 
of SPRY2 and SPRY4 protein expression in SW480-ADH cells treated with the indicated 
doses of 1,25(OH)2D3 for 48 h. (c) SPRY2 expression in SW480-ADH cells treated with the 
indicated hormones (10-7 M) for 48 h. E-cadherin and lamin B were studied as controls of 
1,25(OH)2D3 activity and loading, respectively. (d) Kinetics of SPRY2 repression by 10-7 M 
1,25(OH)2D3 in SW480-ADH cells. (e) Western blot analysis of SPRY2 expression in a panel 
of human colon cancer cell lines that were treated with 10-7 M 1,25(OH)2D3 or vehicle for 48 
h. In (b, d and e) β-actin was used as loading control. The data in (a and e) are expressed as 
the mean ± SEM (n = 3). In (b and d) a representative experiment of three performed is 
shown. 
 
Figure 2.  SPRY2 abrogates the induction of an adhesive epithelial phenotype by 
1,25(OH)2D3 without affecting VDR expression or global transcriptional activity. (a) Phase-
contrast images of Mock and SPRY2 cells treated with 10-7 M 1,25(OH)2D3 or vehicle for 48 
h. Bar: 30 μm. (b) Expression of exogenous (AU5-tagged) and total SPRY2 proteins in Mock 
and SPRY2 cells. β-Actin was used as loading control. (c) Expression of VDR protein in 
Mock and SPRY2 cells treated with 10-7 M 1,25(OH)2D3 or vehicle for 48 h. Total SPRY2 
and β-actin were used as controls. (d) VDR transcriptional activity in Mock and SPRY2 cells. 
The cells were transfected with a VDRE reporter construct and treated with 10-7 M 
1,25(OH)2D3 or vehicle for 48 h and luciferase expression (relative luciferase units, r.l.u.) in 
cell extracts was estimated as described in Materials and Methods. Numbers refer to fold-
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activation values. In (b-d) graphs show the mean ± SEM (n = 4). (e) c-MYC expression in 
Mock and SPRY2 cells treated with 10-7 M 1,25(OH)2D3 or vehicle for the indicated times. 
Exogenous SPRY2 and β-actin were used as controls. In (e), data correspond to a 
representative experiment of three performed.  
 
Figure 3. SPRY2 represses CDH1/E-cadherin and induces ZEB1. (a) qRT-PCR analysis 
of CDH1/E-cadherin RNA expression in Mock and SPRY2 cells treated with 10-7 M 
1,25(OH)2D3 or vehicle for 48 h. SDHA was used for normalization. Mean ± SEM (n = 4). (b) 
Western blot analysis of E-cadherin protein expression in Mock and SPRY2 cells. Exogenous 
(AU5) and total SPRY2 and lamin B were used as controls. Graph shows the quantification. 
Mean ± SEM (n = 6). (c) Immunofluorescence and confocal microscopy analysis of E-
cadherin (green) and SPRY2 (red) expression in Mock and SPRY2 cells. Nuclei stained using 
DAPI (blue) and Merge images are also shown. Bars: 50 μm. Images are representative of 
three independent experiments. (d) qRT-PCR analysis of the RNA levels of SNAI1, SNAI2, 
ZEB1 and ZEB2 in Mock and SPRY2 cells. SDHA was used for normalization. Mean ± SEM 
(n = 3). (e) Western blot analysis of ZEB1 protein expression in Mock and SPRY2 cells 
SW480-ADH cells treated with 10-7 M 1,25(OH)2D3 or vehicle for 48 h. As control we used 
293T cells transiently transfected with a ZEB1 expression plasmid (ZEB1) or an empty vector 
(Mock). Lamin B was used as loading control. Graph shows the quantification. Mean ± SEM 
(n = 3). (f) Activity of the CDH1/E-cadherin promoter in Mock and SPRY2 cells. The cells 
were transfected with the CDH1/E-cadherin promoter construct and the expression of 
luciferase in cell extracts was estimated 48 h later. Mean ± SEM (n = 5). 
 
Figure 4. SPRY2 and E-cadherin repress each other in colon cancer cell lines. (a) 
Expression of SPRY2 and E-cadherin in a panel of colon cancer cell lines. Numbers 
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correspond to values normalized using lamin B and referred to those of SW480-ADH cells. 
(b) Dose-dependent effects of 1,25(OH)2D3 on the expression of SPRY2 and E-cadherin in 
SW480-ADH cells after 48 h treatment. (c) Kinetics of the effects of 10-7 M 1,25(OH)2D3 on 
the expression of SPRY2 and E-cadherin in SW480-ADH cells. (d) qRT-PCR analysis of 
SPRY2 and CDH1/E-cadherin RNA levels in SW480-ADH cells expressing exogenous mouse 
E-cadherin cDNA by stable transfection (E-cadh) or an empty vector (Mock). Mean ± SEM (n 
= 3). (e) Expression of SPRY2 and E-cadherin in SW480-ADH-Mock and SW480-ADH-E-
cadh cells treated with 10-7 M 1,25(OH)2D3 or vehicle for 48 h. Mean ± SEM (n = 3). (f) 
Expression of SPRY2 RNA in LS174T cells cultured at high or low confluence. Mean ± SEM 
(n = 4). (g) Expression of SPRY2 protein in LS174T cells cultured at high or low confluence. 
Mean ± SEM (n = 4). 
  
Figure 5. CDH1/E-cadherin knock-down induces SPRY2 expression. (a) Phase-contrast 
images of SW480-ADH, HT29 and DLD-1 cells infected with lentiviruses expressing either 
control or E-cadherin shRNA. Bars: 30 μm. (b) Expression of SPRY2 and E-cadherin in 
SW480-ADH, HT29 and DLD-1 cells stably expressing control (C) or E-cadherin (E-cadh) 
shRNA. Graph shows the quantification. Mean ± SEM (n = 4). (c) Expression of ZEB1 in 
cells stably transfected with control (C) or E-cadherin (E-cadh) shRNA. Graph shows the 
quantification (SW480-ADH cells). Mean ± SEM (n = 3).  
 
Figure 6. SPRY2 knock-down induces E-cadherin expression. (a) Expression of SPRY2 
and E-cadherin in SW480-ADH cells stably transfected with control (C) or SPRY2  shRNA 
and treated with 10-7 M 1,25(OH)2D3 or vehicle for 48 h. Left, data obtained using three 
shRNA sequences (pools #3, #4, #5); right, using shRNA seq #5. Graphs show the 
quantifications. Mean ± SEM (n = 3). (b) Phase-contrast images of SW480-ADH cells stably 
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transfected with control or SPRY2 (pool #5) shRNA and treated with 10-7 M 1,25(OH)2D3 or 
vehicle for 48 h. Bar: 30 μm. (c) Expression of ZEB1 in SW480-ADH cells stably transfected 
with control or SPRY2 (pool #5) shRNA. SPRY2 and E-cadherin were used as controls and 
lamin B for normalization. 
 
Figure 7. SPRY2 and E-cadherin expression is mutually exclusive in xenografted 
tumours. Immunofluorescence analyses of the expression of SPRY2, E-cadherin and Snail1-
HA proteins in tumours generated in mice by subcutaneous injection of SNAIL-HA cells. (a-
c) The expression of Snail1-HA and E-cadherin are mutually exclusive in tumours (delimited 
by dotted lines). (d-f) SPRY2 expression is restricted to Snail1-HA positive cells. (g) E-
cadherin-expressing cells form small areas of epithelial morphology (delimited by dotted 
lines). (h) SPRY2 is expressed at much higher level in E-cadherin-negative than in E-
cadherin-positive cells. (i) SPRY2 and E-cadherin do not colocalize. Bars: 100 μm. 
 
Figure 8. SPRY2 and E-cadherin have an opposite expression pattern in human 
colorectal carcinomas. Representative analysis of low grade (G1), intermediate grade (G2), 
and high grade (G3) tumours. (a-c) Haematoxylin/eosin (H&E) staining. (d-f) 
Immunofluorescence and confocal microscopy analysis using a Pan-cytokeratin antibody 
(green). (g-i) E-cadherin expression (red). (j-l) SPRY2 expression (green). In (d-l) nuclei 
staining (DAPI) is also shown. (m and n). Images at low or high magnification showing 
SPRY2 expression in a G1 tumour and adjacent normal tissue. Arrowheads indicate the 
preferential localization at the invasive front. Dotted line delimits the magnified area in (n). 
Bars: 100 μm.  
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Figure 9. The levels of SPRY2 and E-cadherin expression correlate negatively in human 
colon carcinomas. E-cadherin and SPRY2 protein expression was analyzed by 
immunofluorescence in serial samples of 34 colon carcinoma patients collected in a tissue 
microarray. Quantification was performed as described in Material and methods. (a) 
Scattergram showing the relation between E-cadherin and SPRY2 levels in each patient 
(Spearman test). (b) Box-plot (Kruskal Wallis test) of SPRY2 expression in tumours with low 
or high E-cadherin expression defined by the median value (167.34 arbitrary units; a.u.). (c) 
Box-plot (Kruskal Wallis test) of SPRY2 expression in low and high grade colon tumours. 
Boxes in the plots include values in the 25%-75% interval; internal lanes represent the 
median. 
 
Figure 10. Model for the control of human colon cancer cell phenotype by the functional 
interplay between 1,25(OH)2D3, SPRY2 and E-cadherin. 1,25(OH)2D3 induces E-cadherin 
and represses SPRY2. Furthermore, ZEB1 is induced by SPRY2 and mediates E-cadherin 
repression, while E-cadherin induces intercellular adhesion and decreases SPRY2 level.  
 










